What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?

被引:80
作者
Petrini, P [1 ]
机构
[1] Karolinska Hosp, Dept Paediat, S-17176 Stockholm, Sweden
关键词
haemophilia; prophylaxis; trough level;
D O I
10.1046/j.1365-2516.2001.00471.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In order to prevent arthropathy, prophylaxis has to start at a young age before recurrent joint bleedings have taken place. The use of central venous lines has facilitated an early beginning to treatment, but due to side-effects, most European paediatricians prefer peripheral injections whenever possible. By starting primary prophylaxis at the age of 1-2 years with one injection weekly, the need for surgical implants may be reduced. In this study, only four of 34 boys born 1988-98 with severe haemophilia A or B needed a Port-a-Cath(R) for primary prophylaxis. Trough levels were measured in these patients and 79% showed a trough level < 1%, while 21% reached a level > 1%. Despite this, joint bleedings during 1998 were rare in both groups [0-4] and 59% of the boys with trough levels < 1% did not report any haemartroses during that year. Mean annual joint bleedings were the same in both groups [0.70, 0.71]. The lowest effective level of factors VIII and IX must be determined individually for each patient on primary or secondary prophylaxis.
引用
收藏
页码:99 / 102
页数:4
相关论文
共 12 条
[1]   A LONGITUDINAL-STUDY OF ORTHOPEDIC OUTCOMES FOR SEVERE FACTOR-VIII-DEFICIENT HEMOPHILIACS [J].
ALEDORT, LM ;
HASCHMEYER, RH ;
PETTERSSON, H ;
EIBL, H ;
GILBERT, M ;
HILGARTNER, M ;
KUNSHACK, M ;
LARRIEU, MJ ;
LEVINE, P .
JOURNAL OF INTERNAL MEDICINE, 1994, 236 (04) :391-399
[2]   Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized [J].
Astermark, J ;
Petrini, P ;
Tengborn, L ;
Schulman, S ;
Ljung, R ;
Berntorp, E .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 105 (04) :1109-1113
[3]   METHODS OF HEMOPHILIA CARE DELIVERY - REGULAR PROPHYLAXIS VERSUS EPISODIC TREATMENT [J].
BERNTORP, E .
HAEMOPHILIA, 1995, 1 :3-7
[4]  
Blanchette VS, 1996, BLOOD COAGUL FIBRIN, V7, pS39
[5]  
CARLSSON M, 1997, EUR J HAEMATOL, V51, P247
[6]   The impact of prophylactic treatment on children with severe haemophilia [J].
Liesner, RJ ;
Khair, K ;
Hann, IM .
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 92 (04) :973-978
[7]   IMPLANTABLE CENTRAL VENOUS CATHETER FACILITATES PROPHYLACTIC TREATMENT IN CHILDREN WITH HEMOPHILIA [J].
LJUNG, R ;
PETRINI, P ;
LINDGREN, AK ;
BERNTORP, E .
ACTA PAEDIATRICA, 1992, 81 (11) :918-920
[8]   Haemophilia prophylaxis in young patients - a long-term follow-up [J].
Lofqvist, T ;
Nilsson, IM ;
Berntorp, E ;
Pettersson, H .
JOURNAL OF INTERNAL MEDICINE, 1997, 241 (05) :395-400
[9]  
MANCOJOHNSON M, 1997, AM J HAEMATOL, V47, P113
[10]   25 YEARS EXPERIENCE OF PROPHYLACTIC TREATMENT IN SEVERE HEMOPHILIA-A AND HEMOPHILIA-B [J].
NILSSON, IM ;
BERNTORP, E ;
LOFQVIST, T ;
PETTERSSON, H .
JOURNAL OF INTERNAL MEDICINE, 1992, 232 (01) :25-32